Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Lymphoma, Non-Hodgkin × venetoclax × Clear all

Phase

Status

Sponsor Class

INDUSTRY 25 OTHER 12 NIH 3 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Leukemia, Myeloid, Acute 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, B-Cell 1 Burkitt Lymphoma 1

Interventions

Etoposide 5 Rituximab 4 Radiotherapy 4 Methotrexate 4 Cytarabine 4 Cyclophosphamide 3 Cisplatin 3 Vincristine 2 Specimen Handling 2 Prednisone 2 Peripheral Blood Stem Cell Transplantation 2 Methylprednisolone 2 Gemcitabine 2 Fenretinide 2 Doxorubicin 2 Carmustine 2 venetoclax 1 tucatinib 1 temsirolimus 1 plerixafor 1 pertuzumab 1 palbociclib 1 olaparib 1 merphos 1 liposomal amphotericin B 1 ixabepilone 1 ibrutinib 1 ibritumomab tiuxetan 1 fludarabine 1 cobimetinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03505944 2021-10-13

VALERIA

Nordic Lymphoma Group

Phase 1/2 Unknown

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡